Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Has Consensus Price Target of $706.87 According to Brokerages

Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have received an average recommendation of “Moderate Buy” from the seventeen brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and fourteen have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $706.87.

Several equities analysts have recently issued reports on MDGL shares. Barclays decreased their price target on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. The Goldman Sachs Group initiated coverage on Madrigal Pharmaceuticals in a research note on Thursday, September 24th. They set a “buy” rating and a $704.00 price objective on the stock. Canaccord Genuity Group raised their price objective on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Wall Street Zen upgraded Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Finally, UBS Group reissued a “buy” rating and issued a $735.00 target price on shares of Madrigal Pharmaceuticals in a research note on Wednesday, October 14th.

Get Our Latest Report on MDGL

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ:MDGL opened at $423.96 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.05 and a quick ratio of 2.78. Madrigal Pharmaceuticals has a 12 month low of $353.54 and a 12 month high of $615.00. The company’s 50-day moving average price is $473.38 and its two-hundred day moving average price is $495.43.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. The firm had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same period last year, the company earned ($5.08) EPS. On average, sell-side analysts predict that Madrigal Pharmaceuticals will post -2.08 EPS for the current year.

Insider Transactions at Madrigal Pharmaceuticals

In other news, CEO William Sibold sold 5,221 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the completion of the sale, the chief executive officer owned 197,746 shares of the company’s stock, valued at $107,255,452.94. This represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bros. Advisors Lp Baker acquired 76,140 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average price of $384.32 per share, for a total transaction of $29,262,124.80. Following the completion of the acquisition, the director owned 2,040,682 shares of the company’s stock, valued at $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 12,660 shares of company stock valued at $6,670,042 over the last quarter. Corporate insiders own 17.60% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC boosted its position in Madrigal Pharmaceuticals by 2.0% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock worth $555,000 after acquiring an additional 20 shares during the last quarter. Fifth Third Bancorp lifted its position in Madrigal Pharmaceuticals by 3.5% during the 3rd quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 28 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Madrigal Pharmaceuticals by 2.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock worth $839,000 after buying an additional 43 shares during the last quarter. ProShare Advisors LLC boosted its stake in shares of Madrigal Pharmaceuticals by 5.5% during the 3rd quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 44 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Madrigal Pharmaceuticals by 35.4% during the 2nd quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after buying an additional 45 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

(Get Free Report)

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Read More

Analyst Recommendations for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.